346 related articles for article (PubMed ID: 9027613)
1. Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials.
Bostwick DG; Aquilina JW
J Cell Biochem Suppl; 1996; 25():156-64. PubMed ID: 9027613
[TBL] [Abstract][Full Text] [Related]
2. The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials.
Bostwick DG; Burke HB; Wheeler TM; Chung LW; Bookstein R; Pretlow TG; Nagle RB; Montironi R; Lieber MM; Veltri RW
J Cell Biochem Suppl; 1994; 19():283-9. PubMed ID: 7529857
[TBL] [Abstract][Full Text] [Related]
3. Intermediate biomarkers for chemoprevention of prostate cancer.
van der Kwast TH
IARC Sci Publ; 2001; 154():199-205. PubMed ID: 11220659
[TBL] [Abstract][Full Text] [Related]
4. The role of prostate-specific antigen in the chemoprevention of prostate cancer.
Crawford ED; DeAntoni EP; Ross CA
J Cell Biochem Suppl; 1996; 25():149-55. PubMed ID: 9027612
[TBL] [Abstract][Full Text] [Related]
5. Risk biomarkers and current strategies for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
[TBL] [Abstract][Full Text] [Related]
6. Prostatic intraepithelial neoplasia is a risk factor for cancer.
Bostwick DG
Semin Urol Oncol; 1999 Nov; 17(4):187-98. PubMed ID: 10632120
[TBL] [Abstract][Full Text] [Related]
7. Apoptotic regulators in prostatic intraepithelial neoplasia (PIN): value in prostate cancer detection and prevention.
Zeng L; Kyprianou N
Prostate Cancer Prostatic Dis; 2005; 8(1):7-13. PubMed ID: 15477876
[TBL] [Abstract][Full Text] [Related]
8. Prospective origins of prostate carcinoma. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia.
Bostwick DG
Cancer; 1996 Jul; 78(2):330-6. PubMed ID: 8674012
[TBL] [Abstract][Full Text] [Related]
9. Target populations and strategies for chemoprevention trials of prostate cancer.
Bostwick DG
J Cell Biochem Suppl; 1994; 19():191-6. PubMed ID: 7823591
[TBL] [Abstract][Full Text] [Related]
10. High-grade prostatic intraepithelial neoplasia with adjacent small atypical glands on prostate biopsy.
Kronz JD; Shaikh AA; Epstein JI
Hum Pathol; 2001 Apr; 32(4):389-95. PubMed ID: 11331955
[TBL] [Abstract][Full Text] [Related]
11. Potential pathologic markers for prostate chemoprevention studies.
Sakr WA; Lucia MS
Urol Clin North Am; 2004 May; 31(2):227-35. PubMed ID: 15123403
[TBL] [Abstract][Full Text] [Related]
12. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
13. Microvessel density as a molecular marker for identifying high-grade prostatic intraepithelial neoplasia precursors to prostate cancer.
Sinha AA; Quast BJ; Reddy PK; Lall V; Wilson MJ; Qian J; Bostwick DG
Exp Mol Pathol; 2004 Oct; 77(2):153-9. PubMed ID: 15351240
[TBL] [Abstract][Full Text] [Related]
14. Apoptotic index as a biomarker in prostatic intraepithelial neoplasia (PIN) and prostate cancer.
Wheeler TM; Rogers E; Aihara M; Scardino PT; Thompson TC
J Cell Biochem Suppl; 1994; 19():202-7. PubMed ID: 7823593
[TBL] [Abstract][Full Text] [Related]
15. Clinical management of premalignant lesions of the prostate. WHO Collaborative Project and Consensus Conference on Public Health and Clinical Significance of Premalignant Alterations in the Genitourinary Tract.
Häggman MJ; Adolfsson J; Khoury S; Montie JE; Norlén J
Scand J Urol Nephrol Suppl; 2000; (205):44-9. PubMed ID: 11144903
[TBL] [Abstract][Full Text] [Related]
16. Is low-grade prostatic intraepithelial neoplasia a risk factor for cancer?
Goeman L; Joniau S; Ponette D; Van der Aa F; Roskams T; Oyen R; Van Poppel H
Prostate Cancer Prostatic Dis; 2003; 6(4):305-10. PubMed ID: 14663472
[TBL] [Abstract][Full Text] [Related]
17. The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues.
Häggman MJ; Macoska JA; Wojno KJ; Oesterling JE
J Urol; 1997 Jul; 158(1):12-22. PubMed ID: 9186314
[TBL] [Abstract][Full Text] [Related]
18. Prostatic intraepithelial neoplasia and prostate cancer.
Montironi R; Santinelli A; Mazzucchelli R
Panminerva Med; 2002 Sep; 44(3):213-20. PubMed ID: 12094135
[TBL] [Abstract][Full Text] [Related]
19. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
[TBL] [Abstract][Full Text] [Related]
20. Production of serum-free and total prostate-specific antigen due to prostatic intraepithelial neoplasia.
Minardi D; Galosi AB; Dell'Atti L; Hanitzsch H; Mario P; Muzzonigro G
Scand J Urol Nephrol; 2002; 36(5):323-9. PubMed ID: 12487735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
